Xiamen Amoytop Biotech Co., Ltd. (688278.SS)
CNY 74.3
(-1.72%)
CNY 74.3
(-1.72%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 709.65 Million CNY | 76.05% |
| 2022 | 404.62 Million CNY | 57.13% |
| 2021 | 260.9 Million CNY | 46.56% |
| 2020 | 179.69 Million CNY | 27.17% |
| 2019 | 135.09 Million CNY | 135.57% |
| 2018 | 68.12 Million CNY | 48.29% |
| 2017 | 40.73 Million CNY | -32.7% |
| 2016 | 56.5 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 157.3 Million CNY | -15.59% |
| 2024 Q3 | 280.28 Million CNY | 21.7% |
| 2024 Q2 | 228.48 Million CNY | 28.35% |
| 2023 Q4 | 203.23 Million CNY | 1.71% |
| 2023 FY | - CNY | 76.05% |
| 2023 Q3 | 199.8 Million CNY | 38.46% |
| 2023 Q1 | 104.38 Million CNY | 18.04% |
| 2023 Q2 | 144.3 Million CNY | 38.24% |
| 2022 Q1 | 72.68 Million CNY | 33.17% |
| 2022 FY | - CNY | 57.13% |
| 2022 Q4 | 88.42 Million CNY | -3.67% |
| 2022 Q3 | 91.79 Million CNY | -10.48% |
| 2022 Q2 | 102.53 Million CNY | 41.06% |
| 2021 Q3 | 72.13 Million CNY | 72.62% |
| 2021 Q4 | 54.58 Million CNY | -24.33% |
| 2021 Q2 | 41.79 Million CNY | -7.41% |
| 2021 Q1 | 45.13 Million CNY | -0.6% |
| 2021 FY | - CNY | 46.56% |
| 2020 Q4 | 45.4 Million CNY | 30.92% |
| 2020 Q1 | 28.29 Million CNY | -43.32% |
| 2020 Q2 | 28.69 Million CNY | 1.39% |
| 2020 Q3 | 34.68 Million CNY | 20.89% |
| 2020 FY | - CNY | 27.17% |
| 2019 Q1 | 4.01 Million CNY | -87.67% |
| 2019 FY | - CNY | 135.57% |
| 2019 Q4 | 49.92 Million CNY | 6.83% |
| 2019 Q3 | 46.73 Million CNY | 157.1% |
| 2019 Q2 | 18.17 Million CNY | 352.73% |
| 2018 Q3 | 21.03 Million CNY | 0.0% |
| 2018 Q4 | 32.56 Million CNY | 54.81% |
| 2018 FY | - CNY | 48.29% |
| 2017 FY | - CNY | -32.7% |
| 2016 FY | - CNY | 0.0% |